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BY-NC-ND license (http://creativecomAbstract Background/purpose: Currently, tigecycline-nonsusceptible Klebsiella pneumoniae
(TNSKP) is mainly reported to emerge following clinical use of tigecycline and is usually poly-
clonal. This study aimed to characterize TNSKP isolated from patients without prior tigecycline
use.
Methods: Twenty-six TNSKP clinical isolates were collected, and carbapenemase and 16S rRNA
methylase genes were identified by polymerase chain reaction and sequencing. Molecular
typing was conducted by pulsed-field gel electrophoresis (PFGE) and multilocus sequence
typing (MLST). Clinical data of patients in the carbapenem-susceptible TNSKP group and the
tigecycline- and carbapenem-nonsusceptible K. pneumoniae (TCNSKP) group were compared.
Results: Of the 26 TNSKP isolates, eight contained both blaKPC-2 and 16S rRNA methylase genes.
In the remaining 18 TNSKP isolates, no carbapenemase gene was detected, and only three had
the 16S rRNA methylase gene. Among the 26 isolates, 24 distinct pulsotypes and 19 sequence
types (STs) were identified by PFGE and MLST, respectively. Six of the eight TCNSKP were ST11,
whereas the remaining 18 TNSKP isolates were assigned to 17 different STs. No patient
received tigecycline prior to the isolation of TNSKP. By comparison, intensive care unitAntibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, China.
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TCNSKP ST11 clone in patients without tigecycline use 963exposure, mechanical ventilation, prior b-lactam/b-lactamase use, and longer hospitalization
were more common for the TCNSKP group than for the carbapenem-susceptible TNSKP group.
Conclusion: TNSKP can occur without tigecycline use, and TCNSKP ST11 is predominant among
them. Further, this report proposes potential risk factors for the occurrence of carbapenem-
nonsusceptibility in TNSKP.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Tigecycline, the first member of the glycylcyclines group of
antibiotics with good in vitro activity against carbapenem-
resistant Klebsiella pneumoniae,1,2 may provide a potential
treatment option as a last resort defense against these
“superbugs”. While tigecycline-nonsusceptible rates among
K. pneumoniae isolates are generally low,3 tigecycline-
nonsusceptible K. pneumoniae (TNSKP) has been reported
to occur following clinical use of the antibiotic.4e7 Data
regarding the clinical features of TNSKP, as well as the
microbiological and the molecular characteristics of TNSKP,
remain scarce. Previously, we reported tigecycline resis-
tance mechanisms for 26 TNSKP isolates, and that efflux
pumps AcrAB and OqxAB played an essential role in tige-
cycline resistance in K. pneumoniae.8
Although tigecycline has been available in China since
the end of 2011, it is not commonly used in clinical practice
because of its high price and limited indications for
hospital-acquired infections. Herein, we report TNSKP
infection or colonization in 26 patients who had not
received tigecycline treatment previously and provide in-
formation concerning the predominance of ST11 among the
tigecycline- and carbapenem-nonsusceptible K. pneumo-
niae (TCNSKP) isolates at Huashan Hospital in Shanghai,
China. We also established the clinical and microbiological
characteristics of the 26 TNSKP isolates, and investigated
the factors that increase the risk of infection or coloniza-
tion with TCNSKP.Methods
Patients and isolates
Patients with TNSKP infection or colonization were identi-
fied among those admitted at Huashan Hospital, Fudan
University, China. Only the first TNSKP was included in this
study when more than one TNSKP isolate was isolated from
the same patient. Twenty-six nonduplicated TNSKP isolates
were identified during a study investigating tigecycline
resistance mechanisms in Enterobacteriaceae.8 Minimum
inhibitory concentrations (MICs) of other antimicrobial
agents were determined by the agar dilution methodology
and interpreted following the recommendations of the
Clinical and Laboratory Standards Institute (CLSI, Wayne,
PA, USA).9 Escherichia coli ATCC 25922 was used as the
quality control strain.Detection of b-lactamase and 16S rRNA methylase
genes
All TNSKP were tested for the presence of various carba-
penemase genes (blaKPC, blaNDM, blaIMP, blaVIM, blaSPM, and
blaSIM) and 16S rRNA methylase genes (armA and rmtB) by
polymerase chain reaction and sequencing as described
previously.10,11
Molecular typing
Pulsed-field gel electrophoresis (PFGE) was performed to
determine genetic relatedness of the isolates using the
restriction enzyme XbaI (TaKaRa Biotechnology Co. Ltd.,
Dalian, China). Multilocus sequence typing (MLST) was
carried out as described earlier.12 The PFGE banding pat-
terns were compared via the BioNumerics version 6.6
software (Applied Maths, Sint-Martens-Latem, Belgium),
and a similarity cutoff of 90% was used.13
Clinical data collection
Clinical information, including demographic data, duration
of hospital stay, day of specimen collection, location of the
patient, healthcare exposure within the prior 6 months,
device use at the time of TNSKP isolation, utilization of
antimicrobial agents prior to TNSKP isolation after the
admission, underlying diseases, and outcomes (died or alive
during hospital stay), were collected. The time of the
TNSKP isolation was defined as the day of collection of the
specimen in which TNSKP bacteria were detected.
Statistical analysis
Contingency data were analyzed by the Fisher’s exact test,
and continuous data were assessed by the Student t test. A
p value < 0.05 was considered as statistically significant,
and the odds ratio was calculated with confidence intervals
of 95% (95% CI). Statistical analyses were carried out using
SPSS 19.0 (SSPS Inc., Chicago, IL, USA).
Results
Of the 26 TNSKP isolates, eight (30.8%) were TCNSKP (mer-
openem MICs, 16e128 mg/mL; imipenem MICs, 4e128 mg/
mL). These eight TCNSKP isolates were resistant to all anti-
microbial agents tested except to colistin (MICs, 0.25e1 mg/
964 Z.-K. Sheng et al.mL), and four were susceptible to fosfomycin. The remain-
ing 18 TNSKP isolates were susceptible to meropenem, imi-
penem, fosfomycin, and colistin, and had a high rate of
susceptibility to piperacillin/tazobactam (83.3%), aztreo-
nam (72.2%), and cefepime (88.9%; Table 1). The most
common sources of isolation were urine (nZ 13), followed
by sputum (nZ 8), bile (nZ 4), and blood (nZ 1; Figure 1).
Of the 26 TNSKP isolates, the eight TCNSKP isolates
carried blaKPC-2 and also harbored a 16S rRNA methylase
gene (armA, n Z 2 and rmtB, n Z 6) in accordance with
their aminoglycoside resistance phenotype. In the remain-
ing 18 carbapenem-susceptible TNSKP isolates, polymerase
chain reaction was negative for the carbapenemase genes
tested, and only three possessed a 16S rRNA methylase
gene (rmtB, n Z 2 and armA, n Z 1).
The 26 TNSKP isolates were assigned to 24 distinct pul-
sotypes and 19 distinct sequence types (STs; Figure 1),
among which ST11 was the predominant ST type (n Z 7,
26.9%), followed by ST37 (n Z 2). Of the eight TCNSKP
isolates, six were ST11, while the other two were ST690 (a
single-locus variant of ST11) and ST39. Among the remain-
ing 18 carbapenem-susceptible TNSKP isolates, 17 STs were
identified, including three new STs designated in this study
as STn1, STn2, and STn3, respectively (Figure 1).Table 1 Antimicrobial susceptibility of tigecycline-nonsuscepti
Patient Isolate
TGC IPM MEM TZP CTX
1 TNSKP8 4 8 32 128/4 32
2 TNSKP25 4 4 32 128/4 128
3 TNSKP15 4 8 16 128/4 16
4 TNSKP7 4 8 32 128/4 128
5 TNSKP12 8 128 128 >128/4 128
6 TNSKP17 8 8 64 >128/4 128
7 TNSKP16 8 8 64 >128/4 128
8 TNSKP11 16 8 64 >128/4 128
9 TNSKP2 16 0.06 0.06 16/4 16
10 TNSKP14 4 0.06 0.06 16/4 0.5
11 TNSKP3 8 0.06 0.06 16/4 8
12 TNSKP5 4 0.06 0.06 128/4 128
13 TNSKP20 16 0.06 0.06 >128/4 128
14 TNSKP23 4 0.06 0.06 8/4 0.2
15 TNSKP1 4 0.06 0.06 16/4 0.5
16 TNSKP22 4 0.06 0.06 8/4 32
17 TNSKP24 4 0.06 0.06 2/4 8
18 TNSKP21 8 0.06 0.06 8/4 0.2
19 TNSKP9 8 0.06 0.06 8/4 0.1
20 TNSKP13 4 0.06 0.06 16/4 8
21 TNSKP26 4 0.06 0.06 2/4 0.0
22 TNSKP6 4 0.06 0.06 16/4 0.2
23 TNSKP18 8 0.06 0.06 8/4 0.2
24 TNSKP4 8 0.06 0.06 128/4 128
25 TNSKP19 4 0.06 0.06 16/4 8
26 TNSKP10 4 0.06 0.06 16/4 1
Tigecycline minimum inhibitory concentrations (MICs) were determine
by the agar dilution method.
AMK Z amikacin; COL Z colistin; CTX Z cefotaxime; FEP Z cefep
MEM Z meropenem; MIC Z minimum inhibitory concentration; MIN
susceptible Klebsiella pneumoniae; TZP Z piperacillin-tazobactam.Of the 26 patients with TNSKP, two outpatients were
excluded since their clinical records were not available.
Thus, the clinical data of the 24 patients were collected
and grouped based on the TNSKP with carbapenem-
resistance (TCNSKP group) or not (carbapenem-suscepti-
ble TNSKP group; Table 2).
Overall, 31 different antibiotics were administered after
admission, prior to the isolation of TNSKP from the 26 pa-
tients, including b-lactams/b-lactamase inhibitors, fluo-
roquinolones, carbapenems, and cephalosporins. However,
tigecycline was not given to any patient before TNSKP
isolation.
Seven (87.5%) of the eight patients with TCNSKP had a
history of intensive care unit (ICU) stay, whereas three
(18.8%) patients in the carbapenem-susceptible TNSKP
group had a history of ICU stay (p < 0.01; odds ratio, 30.33;
95% CI, 2.64e348.96; Table 3). Mechanical ventilation and
b-lactam/b-lactamase inhibitors use were also significantly
more common in the TCNSKP group (both p Z 0.02).
Moreover, the mean interval between patient admission to
this hospital and the isolation of TNSKP was 36 days (range,
7e72 d) in the TCNSKP group and 16 days (range, 0e70 d) in
the TNSKP group (p Z 0.01), suggesting that longer hospi-
talization likely contributes to the isolation of TCNSKP.ble Klebsiella pneumoniae (TNSKP) isolates.
MIC (mg/mL)
FEP AMK FOS LEV MIN COL
8 >128 4 4 >128 0.5
>128 >128 8 32 4 1
16 >128 >256 128 64 0.25
64 >128 >256 128 32 1
64 >128 >256 >128 64 0.25
64 >128 8 128 >128 0.25
64 >128 >256 >128 64 0.25
128 >128 8 >128 >128 0.25
8 0.5 8 16 >128 0.5
0.25 0.5 4 0.5 32 0.25
2 0.5 4 4 >128 0.5
32 128 8 16 32 0.25
32 >128 >256 8 >128 0.5
5 0.125 1 4 0.25 16 0.25
0.25 0.5 8 2 32 0.25
8 0.5 4 4 32 0.5
8 1 4 1 8 0.5
5 0.25 >128 4 32 >128 0.25
25 0.125 1 4 >128 64 0.5
2 >128 8 >128 >128 0.25
6 0.06 1 2 0.06 4 0.5
5 0.125 0.5 2 0.25 16 0.25
5 0.25 1 8 0.5 64 1
0.5 1 4 128 >128 0.25
4 1 8 4 32 0.25
0.5 1 8 128 32 0.5
d by the broth microdilution method, and others were determined
ine; FOS Z fosfomycin; IPM Z imipenem; LEV Z levofloxacin;
Z minocycline; TGC Z tigecycline; TNSKP Z tigecycline-non-
Figure 1. Pulsed-field gel electrophoresis (PFGE) dendrogram of 26 tigecycline-nonsusceptible Klebsiella pneumoniae (TNSKP)
analyzed by BioNumerics, and the corresponding sequence types (STs) of the isolates. A similarity cutoff of 90% was used to group
TNSKP (red dotted line). TNSKP with carbapenem resistance was indicated (red rectangle). ICU Z intensive care unit;
ST Z sequence type.
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In the present study, tigecycline was not prescribed to any
patient prior to TNSKP isolation, which was contrary to
findings of a nested case-control study which revealed the
receipt of tigecycline as the only independent predictor of
subsequent isolation of a tigecycline-resistant K. pneumo-
niae isolate.14 We hypothesized that spontaneous muta-
tions or the use of other types of antibiotics might have
contributed to the emergence of TNSKP in this examina-
tion. It is also possible that TNSKP existed and was
disseminated by other patients who had been treated with
tigecycline, although it is not commonly used in China.
Lin et al15 reported that no major cluster of 36 TNSKP
isolates was identified by PFGE, which was consistent with
the results of our study. However, in the present investiga-
tion, MLST indicated predominance of ST11 among the TNSKP
isolates, in particular TCNSKP isolates (6/8, 75.0%). Zhong
et al16 also established that K. pneumoniae ST11 was the
predominant lineage among tigecycline- and carbapenem-
nonsusceptible isolates. These findings indicated that ST11
exerts an important role in TNSKP, especially TCNSKP.
ST11 is the most common ST among K. pneumoniae
carbapenemase (KPC)-2-producing K. pneumoniae inChina17 and some other regions.18e21 This international
epidemic of the K. pneumoniae ST11 clone may suggest the
presence of selective advantages that facilitate the spread
of carbapenem-resistance among TNSKP isolates. There-
fore, TCNSKP ST11 may have the potential to be extensively
disseminated. Tigecycline and polymyxin are usually rec-
ommended as last resort agents for the treatment of
multidrug-resistant and/or extensively drug-resistant
Gram-negative bacilli such as KPC-producing K. pneumo-
niae. Therefore, the emergence of TCNSKP is a real threat,
especially for those regions and countries (such as China)
where polymyxins are not available for clinical use.
Approaches to control the dissemination of TCNSKP are
urgent. Based on the guidelines for multidrug-resistant
Gram-negative bacteria,22 we suggest: (1) measures such
as enhanced antimicrobial stewardship and infection
control compliance are needed to avoid the emergence
and even outbreak of TCNSKP; (2) efforts such as rein-
forcement of hand hygiene and decolonization are
important to reduce the spread of TCNSKP; and (3) active
surveillance cultures should be performed in patients
predisposed by the conditions mentioned above. In addi-
tion, routine microbiologic surveillance of newly admitted
patients and outpatients may be not recommended,
Table 2 Clinical features of eight patients with tigecycline- and carbapenem-non-susceptible Klebsiella pneumoniae
(TCNSKP) and 16 patients with carbapenem-susceptible tigecycline-nonsusceptible K. pneumoniae (TNSKP).
Isolates Age
(y)/sex






TNSKP11 58/F Craniotomy YES Ommaya reservoir 54 NO Alive
TNSKP16 79/F Guillain-Barre syndrome YES Mechanical ventilation,
urinary catheter
77 NO Alive
TNSKP15 53/M Craniotomy YES Mechanical ventilation 48 YES Alive
TNSKP7 40/F Multiple organ dysfunction








TNSKP25 65/M Craniotomy YES Mechanical ventilation,
Ommaya reservoir
13 YES Alive
TNSKP17 30/F SLE nephritis NO d 21 YES Alive
TNSKP8 88/M Severe pneumonia,
respiratory failure
YES Mechanical ventilation 45 NO Alive
Carbapenem-susceptible TNSKP
TNSKP21 65/M Complicated urinary
tract infection
NO d 22 YES Alive
TNSKP9 51/M Meningitis, severe
pneumonia
YES Urinary catheter 29 YES Alive
TNSKP13 23/M Tuberculous meningitis NO Urinary catheter 7 YES Alive
TNSKP2 54/F Complicated urinary
tract infection
NO PICC 31 YES Alive
TNSKP4 79/F Severe pneumonia NO d 19 YES Alive
TNSKP5 49/M Severe pneumonia NO d 17 YES Alive
TNSKP1 56/M Severe pneumonia NO d 22 YES Alive
TNSKP26 95/M Complicated urinary
tract infection
NO Urinary catheter 21 YES Alive
TNSKP22 75/F Pancreatic carcinoma NO PICC, T-tube drainage 120 NO Died
TNSKP14 76/M Complicated urinary
tract infection
NO Urinary catheter 72 NO Alive
TNSKP6 65/M Cholecystolithiasis NO T-tube drainage 10 NO Alive
TNSKP18 71/F Pancreatic carcinoma NO T-tube drainage 113 NO Alive
TNSKP23 50/M Cholangiocarcinoma NO T-tube drainage 27 NO Alive




TNSKP3 62/M Craniotomy YES Mechanical ventilation,
nasogastric tube
13 YES Alive
TNSKP24 61/F Craniotomy YES Mechanical ventilation 208 NO Alive
ICUZ intensive care unit; PICCZ peripherally inserted central catheter; SLEZ systemic lupus erythematosus; TCNSKPZ tigecycline-
and carbapenem-nonsusceptible Klebsiella pneumoniae; TNSKP Z tigecycline-nonsusceptible K. pneumoniae.
966 Z.-K. Sheng et al.because the rate of TNSKP and TCNSKP isolation is very
low in K. pneumoniae.8
Of note, TNSKP10 (ST11) and TNSKP19 (ST37) isolates
were from outpatients. Although TNSKP isolates may
naturally exist in the community, we cannot rule out the
possibility that these two are hospital-associated TNSKP, as
the outpatients may have a history of hospitalization and
then colonization by TNSKP. Actually, K. pneumoniae ST11
and ST37 have played an essential role in transfer and even
nosocomial outbreak of carbapenem resistance (conferred
by blaKPC and blaNDM respectively), which leads us tosuspect that TNSKP with these two STs may disseminate in
the community.
In conclusion, here we report the identification of
TNSKP in 26 specimens isolated from patients without
prior exposure to tigecycline, and the emergence of
TCNSKP ST11 as the predominant clone in TNSKP. In
addition, ICU exposure, mechanical ventilation, use of b-
lactam/b-lactamase inhibitors, and longer hospitalization
were established as possibly associated with the
occurrence of carbapenem-nonsusceptibility in clinical
TNSKP.
Table 3 Comparison of clinical features between patients with tigecycline- and carbapenem-nonsusceptible K. pneumoniae
(TCNSKP) and those with carbapenem-susceptible tigecycline-nonsusceptible K. pneumoniae (TNSKP).
Risk factor TCNSKP (n Z 8) Carbapenem-susceptible
TNSKP (n Z 16)
p Odds ratio (95% CI)
Male sex (%) 4 (50) 12 (75) 0.36 0.33 (0.56e2.00)
Mean age (y) 58.8 62.7 0.60
ICU exposure (%) 7 (87.5) 3 (18.8) 0.00 30.33 (2.64e348.92)
Interval of patient admission and
TNSKP isolation, mean d (range)
36 (7e72) 16 (0e70) 0.01
Previous hospitalization within 6 mo (%) 4 (50) 10 (62.5) 0.67 1.67 (0.30e9.27)
Recent surgery (%) 4 (50) 7 (43.8) 1.00 1.29 (0.23e7.05)
Device use (%)
Central venous catheter 2 (25) 2 (12.5) 0.58 2.33 (0.26e20.66)
Mechanical ventilation 6 (75) 3 (18.8) 0.02 13.00 (1.70e99.38)
Urinary catheter 3 (37.5) 5 (31.3) 1.00 1.32 (0.22e7.82)
Prior corticosteroid use (%) 1 (12.5) 1 (6.3) 1.00 2.14 (0.12e39.47)
Antibiotic use (%)
b-lactam/b-lactamase inhibitors 5 (62.5) 2 (12.5) 0.02 11.67 (1.49e91.54)
Carbapenems 4 (50) 5 (31.3) 0.41 2.20 (0.39e12.57)
Aztreonam 0 1 (6.3) 1.00
1st-/2nd-generation cephalosporins 1 (12.5) 6 (37.5) 0.35 0.24 (0.02e2.44)
3rd-/4th-generation cephalosporins 4 (50) 4 (25) 0.36 3.00 (0.50e17.95)
Aminoglycosides 1 (12.5) 5 (31.3) 0.62 0.31 (0.03e3.29)
Fluoroquinolones 4 (50) 8 (50) 1.00 1.00 (0.18e5.46)
Fosfomycin 3 (37.5) 0 0.03
Tetracyclines 2 (25) 1 (6.3) 0.25 5.00 (0.38e66.01)
ICU Z intensive care unit; CI Z confidence intervals; TCNSKP Z tigecycline- and carbapenem-nonsusceptible K. pneumoniae;
TNSKP Z tigecycline-nonsusceptible K. pneumoniae.
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